[HTML][HTML] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free …
AR Clamp, EC James, IA McNeish, A Dean, JW Kim… - The Lancet, 2019 - thelancet.com
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-
line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
[HTML][HTML] Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo …
RP Symonds, C Gourley, S Davidson, K Carty… - The Lancet …, 2015 - thelancet.com
Background Patients treated with standard chemotherapy for metastatic or relapsed cervical
cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of …
cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of …
[HTML][HTML] An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of …
M Gore, A Hackshaw, WE Brady, RT Penson… - Gynecologic …, 2019 - Elsevier
Objectives We evaluated four different treatment regimens for advanced-stage mucinous
epithelial ovarian cancer. Methods We conducted a multicenter randomized factorial trial …
epithelial ovarian cancer. Methods We conducted a multicenter randomized factorial trial …
Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc …
RD Morgan, IA McNeish, AD Cook, EC James… - The Lancet …, 2021 - thelancet.com
Background Platinum-based neoadjuvant chemotherapy followed by delayed primary
surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage …
surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage …
[HTML][HTML] Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a …
SP Blagden, AD Cook, C Poole, L Howells… - The Lancet …, 2020 - thelancet.com
Background The ICON8 study reported no significant improvement in progression-free
survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly …
survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly …
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial–ANZGOG 0903
L Mileshkin, R Edmondson, RL O'Connell… - Gynecologic …, 2019 - Elsevier
Background The clinical benefit rate with aromatase inhibitors and the impact of treatment
on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 …
on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 …
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal …
Background Hormonal therapies are commonly prescribed to patients with metastatic
granulosa cell tumours (GCT), based on high response rates in small retrospective studies …
granulosa cell tumours (GCT), based on high response rates in small retrospective studies …
[HTML][HTML] Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
A Olsson-Brown, R Lord, J Sacco, J Wagg… - Endocrine …, 2020 - ec.bioscientifica.com
Materials and methods To characterise the longitudinal clinical course of thyroid dysfunction
in patients from a single, UK regional cancer centre, a retrospective review of patients was …
in patients from a single, UK regional cancer centre, a retrospective review of patients was …
[HTML][HTML] CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
Background: Taxane-induced peripheral neuropathy (TIPN) is an important cause of
premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality …
premature treatment cessation and dose-limitation in cancer therapy. It also reduces quality …
Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous …
ME Gore, A Hackshaw, WE Brady, RT Penson… - 2015 - ascopubs.org
5528 Background: Advanced mEOC responds poorly to standard therapy. It comprises< 8%
pts in ovarian cancer trials, so it is difficult to examine treatment effects in this subgroup. We …
pts in ovarian cancer trials, so it is difficult to examine treatment effects in this subgroup. We …